HELP Latest Headlines

Helus Pharma: Buy Rating Reaffirmed as Phase 3 MDD Program Advances; $70 Price Target Maintained

at www.tipranks.com (Wed, 19-Aug 6:26 AM)

Ibogaine could rise as potential psychedelic treatment with Trump announcement

at seekingalpha.com (Tue, 18-Aug 2:14 PM)

Helus Pharma Bolsters Leadership with Key HR and CNS Drug-Development Appointments

at www.tipranks.com (Tue, 18-Aug 8:08 AM)

Helus Pharma Advances Late-Stage Trials and Strengthens Cash Position Amid Key Leadership Changes

Market Chameleon (Fri, 14-Aug 8:53 AM)

Helus Pharma Advances Toward Phase 3 Results with Early Completion in Major MDD Trial—Durability and Remission Rates Underpin Optimism

Market Chameleon (Tue, 21-Jul 11:07 AM)

Helus Pharma Reaches Key Milestone: Early Enrollment Completion in Phase 3 Study Signals Progress for Novel Depression Treatment

Market Chameleon (Tue, 21-Jul 8:14 AM)

Helus Pharma’s Phase 3 Enrollment Hits 86%: What Sets Its Breakthrough Depression Drug Apart Ahead of Crucial Q4 2026 Data?

Market Chameleon (Fri, 26-Jun 9:43 AM)

Helus Pharma Targets Major Depression With $50 Million Underwritten Offering—Funding Phase 3 HLP003 Data and Expansion

Market Chameleon (Thu, 25-Jun 10:35 AM)

Helus Pharma Raises $50 Million for Phase 3 Depression Drug as Underwritten Offering Priced at $4.85 per Share

Market Chameleon (Wed, 24-Jun 11:09 AM)

Helus Pharma’s $50 Million Offering Aims to Accelerate Key Mental Health Drug Trials

Market Chameleon (Wed, 24-Jun 7:06 AM)